Evidence map›Paper›PMID 34838331›Full record

ArticlePathology2022

Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection.

Riham Abdel-Hamid Haroun, Waleed H Osman, Rasha E Amin, Ahmad K Hassan, Waleed S Abo-Shanab, Asmaa M Eessa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Riham Abdel-Hamid HarounDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt. Electronic address: rihamharoun8@gmail.com.
Waleed H OsmanDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.
Rasha E AminDepartment of Clinical and Chemical Pathology, Faculty of Medicine, Port-Said University, Port-Said, Egypt.
Ahmad K HassanDepartment of Zoology, Faculty of Science, Port-Said University, Port-Said, Egypt.
Waleed S Abo-ShanabDepartment of Radiodiagnosis, Faculty of Medicine, Port-Said University, Port-Said, Egypt.
Asmaa M EessaDepartment of Geriatric Medicine and Gerontology, Faculty of Medicine, Port-Said University, Port-Said, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of human miRNAs involved in coronavirus-host interplay is important due to the current COVID-19 pandemic. Therefore, this study aimed to measure the circulating plasma miR-155 expression level in COVID-19 patients and healthy controls to investigate its roles in the pathogenesis and severity of COVID-19 disease and to assess its usefulness as a clinical biomarker for the detection of COVID-19 disease and the severity of infection. A total of 150 COVID-19 patients and 50 controls were enrolled into our study. Beside the routine laboratory work and chest computed tomography (CT) scans of COVID-19 patients, plasma miR-155 expression level was measured using reverse transcription quantitative real-time PCR (RT-qPCR) technique. Our results demonstrated increased miR-155 expression level in COVID-19 patients compared to controls, in severe compared to moderate COVID-19 patients, and in non-survival compared to survival COVID-19 patients. miR-155 expression level also had significant correlation with clinicopathological characteristics of COVID-19 patients such as chest CT findings, CRP, ferritin, mortality, D-dimer, WBC count, and lymphocytes and neutrophils percentages. Also, our results showed that the area under the curve (AUC) for miR-155 was 0.986 with 90% sensitivity and 100% specificity when used as a biomarker for the detection of COVID-19 disease; while in detection of severity of COVID-19 disease, AUC for miR-155 was 0.75 with 76% sensitivity and specificity. From these results we can conclude that miR-155 has a crucial role in the pathogenesis and severity of COVID-19; also, it could be a good diagnostic clinical biomarker for the detection of COVID-19 disease and the severity of infection.

Indexed as

AdultBiomarkersCOVID-19FemaleHumansMaleMicroRNAsMiddle AgedSARS-CoV-2Sensitivity and SpecificityBiomarkersMicroRNAsMIRN155 microRNA, humanCoronavirusesCOVID-19microRNAs (miRNAs)miR-155SARS-CoV-2 infection

Identifiers

PMID34838331
PMCPMC8570980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.